Status:
ACTIVE_NOT_RECRUITING
Impact of ILM Peeling in RRD/ I-Peel
Lead Sponsor:
Berner Augenklinik
Conditions:
Retinal Detachment
Eligibility:
All Genders
18-110 years
Phase:
NA
Brief Summary
Retinal detachment is associated with a substantial risk of re-detachment in 10-20% and to the formation of secondary epiretinal membranes in up to 15%. Relevant postoperative vision loss is encounter...
Eligibility Criteria
Inclusion
- primary rhegmatogenous retinal detachment
- of legal age (18 years or older)
- in case of bilateral retinal detachment, only the first-affected eye will be included
Exclusion
- pre-existing functional and morphological changes to the macula, hindering visual recovery (amblyopia, trauma, macular degeneration)
- advanced retinal detachment with PVR stage C2 or more
- eyes pre-operated within six months prior to the development of RD
- state after any vitreoretinal surgery
- state after complicated cataract surgery, including aphakia and anterior chamber lens implantation
- patients with increased risk profiles
- myopia magna (≥7 diopters)
- advanced diabetic retinopathy
- any chronic ocular or systemic inflammatory disease
- any other proliferative systemic disease or condition associated with impaired wound healing
Key Trial Info
Start Date :
February 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04767555
Start Date
February 23 2022
End Date
June 1 2026
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Berner Augenklinik
Bern, Canton of Bern, Switzerland, 3007